1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Strategy

Stada Seeking OTC Acquisitions After Strong 2018 As Private-Equity Owners Begin To Flex Muscles

 
• By Tom Gallen

Germany's Stada is on the look out for consumer health acquisitions globally that can help it reach its ambition to grow faster than the market in 2019. The firm's new private-equity owners are backing CEO Peter Goldschmidt's plan to take the Branded Products division to the next level.

Stada_HQ
• Source: Stada

“Rapid expansion” of its consumer health-focused Branded Products division through acquisitions is a core focus for Stada Arzneimittel AG in 2019 as its private-equity owners look to ramp up sales and earnings at the unit.

Stada is seeking “value-added acquisitions” to grow Branded Products. “These could be pharmaceutical products or entire companies, as long as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Haleon Takes Full Control Of China JV

 
• By Tom Gallen

Haleon finalizes deal to make its China joint venture a wholly-owned subsidiary in move to "drive category growth in one of the fastest growing OTC markets globally."

Opella Claims Sustainability Leadership Position With Global B Corp Certification

 
• By Tom Gallen

Cutting greenhouse gas emissions and obtaining its electricity from renewable sources has helped Opella earn global B Corp certification.

People On The Move: Appointments At Haleon, Nestlé, Cornerstone

 
• By Tom Gallen

A round up of the latest European health & wellness moves: Haleon names Lauder's Haney as R&D chief; Nestle nominates Isla for board chair; Cornerstone appoints Stada's Ed Round.

Navamedic Adds OTC Naloxone With DNE Pharma Acquisition

 
• By Tom Gallen

Norway's Navamedic will move into the addiction treatment market with the acquisition of DNE Pharma, adding to its portfolio an OTC opioid overdose reversal spray.

More from Business

Stada CEO Has ‘Big Hopes’ For AI-Driven Personalized Healthcare

 
• By David Ridley

“Harnessing AI’s astounding abilities to improve people’s lives and relieve overburdened healthcare systems is one of the great opportunities of our time,” argues Stada CEO Peter Goldschmidt in the company's Health Report 2025.

People On The Move: Appointments At Haleon, Nestlé, Cornerstone

 
• By Tom Gallen

A round up of the latest European health & wellness moves: Haleon names Lauder's Haney as R&D chief; Nestle nominates Isla for board chair; Cornerstone appoints Stada's Ed Round.

Navamedic Adds OTC Naloxone With DNE Pharma Acquisition

 
• By Tom Gallen

Norway's Navamedic will move into the addiction treatment market with the acquisition of DNE Pharma, adding to its portfolio an OTC opioid overdose reversal spray.